Merz Pharma to Invest Over €100 Million in Dessau Facility Expansion

Merz Pharma is significantly increasing production and logistics capacity at its Dessau-Roßlau site in Germany. The company announced an investment of over 100 million euros to expand the facility by 2028.

The investment includes a new packaging line and is part of a broader strategy to enhance manufacturing and warehousing capabilities. Merz stated that the expansion is a response to the growing worldwide demand for neurotoxins, used in medical and aesthetic treatments.

Philip Burchard, CEO of Merz Group, expressed confidence in Germany as an industrial location. "We are convinced that we can produce competitively internationally here in the long term," Burchard stated. He added that the expansion aims to consolidate the value chain at the Dessau site.

Local officials, including Sachsen-Anhalt's Minister-President Sven Schulze, welcomed the investment, highlighting its benefits for the company, its employees, and the regional economy. Merz Group, headquartered in Frankfurt, employs approximately 5,500 people globally, with around 450 working at the Dessau facility.